Advertisement

Archives of Osteoporosis

, 11:25 | Cite as

A systematic review of intervention thresholds based on FRAX

A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation
  • John A. KanisEmail author
  • Nicholas C. Harvey
  • Cyrus Cooper
  • Helena Johansson
  • Anders Odén
  • Eugene V. McCloskey
  • The Advisory Board of the National Osteoporosis Guideline Group
Review

Abstract

Summary

This systematic review identified assessment guidelines for osteoporosis that incorporate FRAX. The rationale for intervention thresholds is given in a minority of papers. Intervention thresholds (fixed or age-dependent) need to be country-specific.

Introduction

In most assessment guidelines, treatment for osteoporosis is recommended in individuals with prior fragility fractures, especially fractures at spine and hip. However, for those without prior fractures, the intervention thresholds can be derived using different methods. The aim of this report was to undertake a systematic review of the available information on the use of FRAX® in assessment guidelines, in particular the setting of thresholds and their validation.

Methods

We identified 120 guidelines or academic papers that incorporated FRAX of which 38 provided no clear statement on how the fracture probabilities derived are to be used in decision-making in clinical practice. The remainder recommended a fixed intervention threshold (n = 58), most commonly as a component of more complex guidance (e.g. bone mineral density (BMD) thresholds) or an age-dependent threshold (n = 22). Two guidelines have adopted both age-dependent and fixed thresholds.

Results

Fixed probability thresholds have ranged from 4 to 20 % for a major fracture and 1.3–5 % for hip fracture. More than one half (39) of the 58 publications identified utilised a threshold probability of 20 % for a major osteoporotic fracture, many of which also mention a hip fracture probability of 3 % as an alternative intervention threshold. In nearly all instances, no rationale is provided other than that this was the threshold used by the National Osteoporosis Foundation of the USA. Where undertaken, fixed probability thresholds have been determined from tests of discrimination (Hong Kong), health economic assessment (USA, Switzerland), to match the prevalence of osteoporosis (China) or to align with pre-existing guidelines or reimbursement criteria (Japan, Poland). Age-dependent intervention thresholds, first developed by the National Osteoporosis Guideline Group (NOGG), are based on the rationale that if a woman with a prior fragility fracture is eligible for treatment, then, at any given age, a man or woman with the same fracture probability but in the absence of a previous fracture (i.e. at the ‘fracture threshold’) should also be eligible. Under current NOGG guidelines, based on age-dependent probability thresholds, inequalities in access to therapy arise especially at older ages (≥70 years) depending on the presence or absence of a prior fracture. An alternative threshold using a hybrid model reduces this disparity.

Conclusion

The use of FRAX (fixed or age-dependent thresholds) as the gateway to assessment identifies individuals at high risk more effectively than the use of BMD. However, the setting of intervention thresholds needs to be country-specific.

Keywords

Assessment guidelines Calibration Discrimination FRAX Intervention threshold 

Abbreviations

AACE

American Association of Clinical Endocrinologists

ACR

American College of Rheumatology

AUC

Area under the receiver operating characteristic (ROC) curve

BMD

Bone mineral density

BMI

Body mass index

CAROC

Canadian Association of Radiologists and Osteoporosis Canada

CI

Confidence interval

CRF

Clinical risk factor

DXA

Dual-energy X-ray absorptiometry

ECTS

European Calcified Tissue Society

EFPIA

European Federation of Pharmaceutical Industry Associations

ESCEO

European Society for Clinical and Economic Aspects of Osteoporosis

FRAX

WHO fracture risk assessment tool.

HF

Hip fracture

HSOO

Hungarian Society for Osteoporosis and Osteoarthrology

IOF

International Osteoporosis Foundation

ISCD

International Society of Clinical Densitometry

JSBMR

Japanese Society for Bone and Mineral Research

MOF

Major osteoporotic fracture

NCGC

National Clinical Guideline Centre

NCGC

National Clinical Guideline Centre

NICE

National Institute for health and Clinical Excellence

NNF

Number Needed to FRAX

NNS

Number needed to scan

NOF

National Osteoporosis Foundation, US

NOFSA

National Osteoporosis Foundation of South Africa

NOGG

National Osteoporosis Guideline Group, UK

NRI

Net reclassification improvement (I)

OST

Osteoporosis Self-Assessment Tool

OSTPRE

Kuopio Osteoporosis Risk Factor and Prevention - study

PSTF

US Preventive Services Task Force

QALY

Quality-adjusted life year

QALY

Quality-adjusted life year

QFracture

A fracture risk assessment tool

RCP

Royal College of Physicians, London

ROC

Receiver operating characteristics

SCOOP

Screening of older women for prevention of fracture - study

SCORE

Simple Calculated Osteoporosis Risk Estimation Tool

SD

Standard deviation

SIGN

Scottish Intercollegiate Guidelines Network

SIOMMMS

Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro

TBS

Trabecular bone score

THIN

The Health Improvement Network

T-score

The number of SD units that BMD differs from the young healthy reference population

WHO

World Health Organization

YAM

Young adult mean values for BMD

Notes

Acknowledgments

We are grateful to the University of Southampton and the International Osteoporosis Foundation for their help with the literature searches. The manuscript was appraised by the members of the Committee of Scientific Advisors of the International Osteoporosis Foundation and the National Osteoporosis Guideline Group (UK) and we appreciate their constructive reviews. We are grateful to the International Osteoporosis Foundation and the National Osteoporosis Guideline Group for their endorsement of this paper.

Compliance with ethical standards

Conflicts of interest

Professor Kanis led the team that developed FRAX as director of the WHO Collaborating Centre for Metabolic Bone Diseases; he has no financial interest in FRAX. Professors McCloskey, Oden, Harvey and Dr Johansson are members of the FRAX team. Professors Cooper, Kanis, Harvey and McCloskey are members of the Advisory Board of the National Osteoporosis Guideline Group. Ken E Poole, Neil Gittoes and Sally Hope declare no competing interests with respect to this paper.

Funding source

None.

Glossary

Age-dependent threshold

Intervention or assessment threshold of fracture probability that varies with age

Assessment threshold

The fracture probability at which further assessment id recommended (usually BMD)

Fixed threshold

Intervention or assessment threshold of fracture probability that is fixed over all ages

Fracture threshold

The average probability of fracture for a specific age

Hybrid threshold

Intervention or assessment threshold of fracture probability that partly varies with age and is partly fixed

Intervention threshold

For this report, the fracture probability at which treatment is recommended

Major osteoporotic fracture

Fracture of hip, spine (clinical), distal forearm or humerus.

NOGG strategy

The strategy that describes intervention or assessment threshold of fracture probability that varies with age

Osteopenia

In this report, BMD defined: a T-score of between −1 and −2.5

Osteoporosis

In this report, BMD defined: a T-score of <−2.5

References

  1. 1.
    Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRefGoogle Scholar
  2. 2.
    Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Kanis JA, Borgström F, Compston J et al (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRefGoogle Scholar
  6. 6.
    Hui SL, Slemenda CW, Johnston CC Jr (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995PubMedCrossRefGoogle Scholar
  8. 8.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. Accessed https://www.shef.ac.uk/FRAX/reference.aspx 14 July 2015
  9. 9.
    Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427. doi: 10.1136/bmj.e3427 PubMedCrossRefGoogle Scholar
  10. 10.
    Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRefGoogle Scholar
  11. 11.
    National Institute for Health and Care Excellence (2014) NICE clinical guideline 146. Osteoporosis: assessing the risk of fragility fracture. London, UK. https://www.nice.org.uk/guidance/cg146, Accessed18 May 2015
  12. 12.
    Kanis JA, Compston J, Cooper C et al (2016) SIGN guidelines for Scotland. BMD vs. FRAX vs. QFracture. Calcif Tissue Int 98:417–425PubMedCrossRefGoogle Scholar
  13. 13.
    Collins GS, Mallett S, Altman DG (2011) Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 342:d3651PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRefGoogle Scholar
  15. 15.
    Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX with and without BMD. Calcif Tissue Int 90:1–13PubMedCrossRefGoogle Scholar
  16. 16.
    Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRefGoogle Scholar
  17. 17.
    Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRefGoogle Scholar
  19. 19.
    Middleton RG, Shabani F, Uzoigwe CE, Shoaib A, Moqsith M, Venkatesan M (2012) FRAX and the assessment of the risk of developing a fragility fracture. J Bone Joint Surg 94B:1313–1320Google Scholar
  20. 20.
    Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRefGoogle Scholar
  21. 21.
    Leslie WD, Lix LM, Johansson H, Oden A, McLoskey EV, Kanis JA, for the Manitoba Bone Density Program (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847PubMedCrossRefGoogle Scholar
  22. 22.
    Johansson H, Kanis JA, Odén A et al (2014) Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 95:428–435PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, Hans D (2014) Lumbar spine texture enhances ten-year fracture probability assessment. Osteoporos Int 25:2271–2277PubMedCrossRefGoogle Scholar
  24. 24.
    McCloskey EV, Odén A, Harvey NC et al (2015) Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 96:500–509PubMedCrossRefGoogle Scholar
  25. 25.
    McCloskey EV, Odén A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its dependence on FRAX. J Bone Miner Res 31:940–948PubMedCrossRefGoogle Scholar
  26. 26.
    Leslie WD, Lix LM, Morin SN et al (2015) Adjusting hip fracture probability in men and women using hip axis length: the Manitoba bone density database. J Clin Densitom. doi: 10.1016/j.jocd.2015.07.004 Google Scholar
  27. 27.
    Masud T, Binkley N, Boonen S, Hannan MT, FRAX® Position Development Conference Members (2011) Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:194–204PubMedCrossRefGoogle Scholar
  28. 28.
    Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation ( IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57PubMedCrossRefGoogle Scholar
  29. 29.
    Papaioannou A, Morin S, Cheung AM et al (2010) (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Dawson-Hughes B, National Osteoporosis Foundation Guide Committee (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465PubMedCrossRefGoogle Scholar
  31. 31.
    Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7:3–20PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Scottish Intercollegiate Guidelines Network (SIGN) (2015) Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015. (SIGN publication no. 142). [March 2015]. Available from URL: http://www.sign.ac.uk accessed 11 May 2015
  33. 33.
    Schurman L, Bagur A, Claus-Hemberg H, Messina OD et al (2013) Guias 2012 para el diagnostico, la prevencion y el tratamiento de la osteoporosis. Medicina (Buenos Aires) 73:55–74Google Scholar
  34. 34.
    Wu CH, McCloskey EV, Lee JK et al (2014) Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region. J Clin Densitom 17:150–155PubMedCrossRefGoogle Scholar
  35. 35.
    Pereira RM, Carvalho JF, Paula AP et al (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52:580–593, English, Portuguese PubMedCrossRefGoogle Scholar
  36. 36.
    Borissova A-M, Zacharieva S, Boyanov M et al (2013) Recommendations for good clinical practice in osteoporosis. http://www.iofbonehealth.org/guideline-references#ref_42 Accessed 22 Oct 2015
  37. 37.
    Fouda MA, Khan AA, Sultan MS, Rios LP, McAssey K, Armstrong D (2012) Evaluation and management of skeletal health in celiac disease: position statement. Can J Gastroenterol 26:819–829PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Zhang Z, Gao B, Liu Z (2012) Fracture risk assessment tool (FRAX) for osteoporosis diagnosis and treatment. Chin J Osteoporos 18:589–595Google Scholar
  39. 39.
    Curković B, Grazio S, Babić-Naglić D, Anić B, Vlak T, Hanih M (2008) Recommendations of the Croatian Society for Rheumatology for prevention, diagnostics and treatment of post-menopausal osteoporosis. Reumatizam 55:26–30, Croatian Google Scholar
  40. 40.
    Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, on behalf of the ESMO Guidelines Working Group (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(suppl 3):124–137CrossRefGoogle Scholar
  41. 41.
    Brincat M, Calleja-Agius J, Erel CT et al (2011) EMAS position statement: bone densitometry screening for osteoporosis. Maturitas 68:98–101PubMedCrossRefGoogle Scholar
  42. 42.
    Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913PubMedCrossRefGoogle Scholar
  43. 43.
    Cortet B, Lartigau E, Caty A et al (2012) Androgen deprivation therapy for prostate cancer and osteoporotic risk. Progres En Urologie 22:S31–S38PubMedCrossRefGoogle Scholar
  44. 44.
    Dachverband Osteologie e.V (2011) DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20:55–74, http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/osteology/contents/archive/issue/special (Accessed 19 May 2012)
  45. 45.
    Osteoporosis Society of Hong Kong (2013) OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(suppl 2):3–40Google Scholar
  46. 46.
    Meeta, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2013) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations. J Midlife Health 4:107–126. doi: 10.4103/0976-7800.115293 PubMedPubMedCentralGoogle Scholar
  47. 47.
    Lewiecki EM, Compston JE, Miller PD et al (2011) Official Positions for FRAX® bone mineral density and FRAX® simplification. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:226–236PubMedCrossRefGoogle Scholar
  48. 48.
    Irish Osteoporosis Society (2011) Osteoporosis guidelines for health professionals. Pp1-78. Accessed 14 Oct 2015 www.irishosteoporosis.ie
  49. 49.
    Adami S, Bertoldo F, Brandi ML (2009) Linee guida per la diagnosi, prevenzione e terapia dell’osteoporosi [Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMedGoogle Scholar
  50. 50.
    Maalouf G, Bachour F, Issa M et al (2012) Guidelines for fragility fracture in Lebanon. J Med Liban 60:153–158PubMedGoogle Scholar
  51. 51.
    Sociedad Iberoamericana de Osteología y Metabolismo Mineral [Iberoamerican Society of Osteology and Mineral Metabolism] (2009) Osteoporosis: prevention, diagnosis, and treatment. http://www.iofbonehealth.org/sites/default/files/PDFs/National%20Guidelines/SIBOMMConsensus-2009-english.pdf Accessed 3 Nov 2015
  52. 52.
    Latvian Osteoporosis and Metabolic Diseases Association (2012) Osteporosis Clinical Guidelines [Osteoporozes klīniskās vadlīnijas]. Nacionālais veselības dienests. Accessed Jan 2013 http://www.vmnvd.gov.lv/lv/420-kliniskas-vadlinijas/klinisko-vadliniju-datu-baze/registretas-2012gada
  53. 53.
    Conseil Scientifique, Domaine de la Santé, Analyses de laboratoire (2010) Ostéoporose. Accessed 22 October 2015 http://www.conseil-scientifique.lu/index.php?id=84
  54. 54.
    Peña-Ríos DH, Cisneros-Dreinhofer FA, del Pilar De la Peña-Rodríguez M et al (2015) Consenso de diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica mexicana [Consensus for diagnosis and treatment in Mexican women with postmenopausal osteoporosis]. Med Int Méx 31:596–610Google Scholar
  55. 55.
    Dutch Institute for Healthcare Improvement (CBO) (2011) Richtlijn Osteoporose en fractuurpreventie, derde herziening. CBO, UtrechtGoogle Scholar
  56. 56.
    Romanian Ministry of Health (2010) Guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Order number 1322/2010. (www.ms.ro). Accessed 13 March 2015
  57. 57.
    Czerwiński E, Badurski J, Lorenc R, Osieleniec J (2010) Guidelines on the diagnosis of osteoporosis and assessment of fracture risk in Poland. Ortop Traumatol Rehabil 12(2):194–200, English, [Polish] PubMedGoogle Scholar
  58. 58.
    Al-Saleh Y, Sulimani R, Sabico S et al (2015) Guidelines for osteoporosis in Saudi Arabia: recommendations from the Saudi Osteoporosis Society. Ann Saudi Med 35:1–12PubMedGoogle Scholar
  59. 59.
    International Osteoporosis Foundation guideline references, Slovakia http://www.iofbonehealth.org/guideline-references#ref_27 Accessed 22 Oct 2015
  60. 60.
    Ministry of Health (2010) Osteoporosis: Ministry of Health Practice Guidelines. Ministry of Health, SingaporeGoogle Scholar
  61. 61.
    Rabar S, Lau R, O’Flynn N, Li L, Barry P, on behalf of the Guideline Development Group (2012) Risk assessment of fragility fractures: summary of NICE guidance. BMJ 345:e3698PubMedCrossRefGoogle Scholar
  62. 62.
    American Association of Clinical Endocrinologists (2010) Medial guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(suppl 3):1–37Google Scholar
  63. 63.
    Tosi LL, Dell RM (2012) AAOS. Challenging orthopaedics to reduce osteoporotic hip fractures, 2012. http://www.aaos.org/news/aaosnow/may09/research5.asp (Accessed 6 Nov 2015).
  64. 64.
    Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:404–415PubMedCrossRefGoogle Scholar
  65. 65.
    Lim LS, Hoeksma LJ, Sherin K (2009) Screening for osteoporosis in the adult US population: ACPM position statement on preventive practice. Am J Prev Med 36:366–375PubMedCrossRefGoogle Scholar
  66. 66.
    Kanis JA (2013) Commentary on guidelines on postmenopausal osteoporosis—Indian Menopause Society. J Midlife Health 4:129–131, Available from: http://www.jmidlifehealth.org/text.asp?2013/4/2/129/
  67. 67.
    National Osteoporosis Foundation (2015) Clinician’s guide to prevention and treatment of osteoporosis. http://nof.org/hcp/resources/913 Accessed 9 Feb 2015
  68. 68.
    Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2010—stöd för styrning och ledning. Preliminär version. Artikelnr 2010-11-15. Published at www.socialstyrelsen.se Accessed 3 Nov 2015
  69. 69.
    Mazokopakis EE, Starakis IK (2011) Recommendations for diagnosis and management of osteoporosis in COPD men. ISRN Rheumatol 2011:901416. doi: 10.5402/2011/901416 PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Arznei & Vernunft (2010) Osteoporose. Knochenbruch- Krankheit. Pharmig, Verband der pharmazeutischen Industrie ÖsterreichsGoogle Scholar
  71. 71.
    Body J-J (2012) Aromatase inhibitors-induced bone loss in early breast cancer. Bone Key Rep 1:201. doi: 10.1038/bonekey.2012.201 CrossRefGoogle Scholar
  72. 72.
    British Columbia Medical Association (2012) Osteoporosis: diagnosis, treatment and fracture prevention. British Columbia Medical Association and British Columbia Ministry of healthGoogle Scholar
  73. 73.
    Khan A, Fortier M (2014) Osteoporosis in menopause. J Obstet Gynaecol Can 36(9):S1–S15CrossRefGoogle Scholar
  74. 74.
    Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197PubMedCrossRefGoogle Scholar
  75. 75.
    Stepan J (2009) Algorithm of treatment of glucocorticoid induced osteoporosis—search for criteria. Vnitr Lek 55:448–454PubMedGoogle Scholar
  76. 76.
    Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 23:2567–2576, and erratum Osteoporos Int 23: 2577 PubMedCrossRefGoogle Scholar
  77. 77.
    Koski AM (2013) Glukokortikoidin aiheuttaman osteoporoosin hoitokaavio. http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=ima02292 Accessed 4 Nov 2015
  78. 78.
    Makras P, Paiopoulos G, Lyritis GP (2012) 2011 Guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38–42PubMedGoogle Scholar
  79. 79.
    Makras P, Athanasakis K, Boubouchairopoulou N et al (2015) Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int 26:1949–1957PubMedCrossRefGoogle Scholar
  80. 80.
    Cheung E, Kung AWC, Tan KCB (2014) Outcomes of applying the NOF, NOGG and Taiwanese guidelines to a cohort of Chinese early postmenopausal women. Clin Endocrinol 80:200–207CrossRefGoogle Scholar
  81. 81.
    Lakatos P, Szekeres L, Takács I et al (2011) Diagnostic and therapeutic guidelines for the age-related and glucocorticoid-induced osteoporosis—2011, Hungary. Magyar Reumatol 1:28–33, Hungarian Google Scholar
  82. 82.
    Nakatoah S, Takemaru Y (2013) Application of the fracture risk assessment tool (FRAX®) and determination of suitable cut-off values during primary screening I specific health check-ups in Japan. J Bone Miner Metab 31:674–680CrossRefGoogle Scholar
  83. 83.
    Chakhtoura M, Baddoura R , El-Hajj Fuleihan G (2013) Lebanese FRAX-based osteoporosis guidelines. http://www.osteos.org.lb/admin/uploads/Full%20document.pdf Accessed 19 Oct 2015
  84. 84.
    Malaysian Osteoporosis Society (2012) Clinical guidance on management of osteoporosis. http://www.iofbonehealth.org/sites/default/files/PDFs/National%20Guidelines/Malaysia_CG_Mgmt_Osteoporosis_2012-0912-final.pdf Accessed 14 Oct 2015
  85. 85.
    Yeap SS, Hew FL, Lee JK et al (2013) The Malaysian clinical guidance on the management of postmenopausal osteoporosis, 2012: a summary. Int J Rheum Dis 16:30–40PubMedCrossRefGoogle Scholar
  86. 86.
    Cymet-Ramírez J, Cisneros-Dreinhofer FA, Alvarez-Martínez MM et al (2011) Diagnosis and treatment of osteoporosis. Position of the Mexican College of Orthopedics and Traumatology. Acta Ortop Mex 25:303–312, Spanish PubMedGoogle Scholar
  87. 87.
    Li-Yu J, Perez EC, Cañete A, Bonifacio L et al (2011) Clinical Practice Guidelines Task Force Committee on Osteoporosis. Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–238PubMedCrossRefGoogle Scholar
  88. 88.
    Badurski JE, Kanis JA, Johansson H et al (2011) The application of FRAX (R) to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn 121:148–154PubMedGoogle Scholar
  89. 89.
    Lorenc R, Głuszko P, Karczmarewicz E et al (2011) Polish recommendations on the diagnosis and treatment of osteoporosis. Medycyna Praktyczna(Reumatologia) Special Edition 1/2011 [Polish]Google Scholar
  90. 90.
    Badurski J, Jeziernicka E, Dobrenko A et al (2011) The characteristics of osteoporotic fractures in the region of Bialystok (BOS-2). The application of the WHO algorithm, FRAX (R) BMI and FRAX (R) BMD assessment tools to determine patients for intervention. Endokrynol Pol 62:290–298PubMedGoogle Scholar
  91. 91.
    Gluszko P, Lorenc RS, Karczmarewicz E, Misiorowski W, Jaworski M (2014) Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. Pol Arch Med Wewn 124:255–263PubMedGoogle Scholar
  92. 92.
    Goncalves MJ, Rodrigues AM, Canhao H, Fonseca JE (2013) Osteoporosis: from bone biology to individual treatment decision. Acta Med Port 26:445–455PubMedGoogle Scholar
  93. 93.
    Amin TT, Al Owaifeer A, Al-Hashim H et al (2013) Osteoporosis among older Saudis: risk of fractures and unmet needs. Arch Osteoporos 8:118PubMedCrossRefGoogle Scholar
  94. 94.
    Niemethova E, Killinger Z, Payer J (2013) Fracture risk prediction with FRAX in Slovak postmenopausal women. Cent Eur J Med 8:571–586Google Scholar
  95. 95.
    Kocjan T, Prezelj J, Pfeifer M, Sever MJ, Cokolic M, Zavratnik A (2013) Guidelines for the detection and treatment of osteoporosis. Zdrav Vestn 82:207–217Google Scholar
  96. 96.
    International Osteoporosis Foundation guideline references, Slovenia http://www.iofbonehealth.org/guideline-references#ref_38 Accessed 22 Oct 2015
  97. 97.
    Hough S, Ascott-Evans B-H, Brown SL et al for the National Osteoporosis Foundation of South Africa (NOFSA) (2010) NOFSA guideline for the diagnosis and management of osteoporosis. Available online at: www.jemdsa.co.za and www.osteoporosis.org.za Accessed 22 Oct 2015Google Scholar
  98. 98.
    Kim JW, Jeon YJ, Baek DH, Kim TN, Chang JS (2014) Percentage of the population at high risk of osteoporotic fracture in South Korea: analysis of the 2010 Fifth Korean National Health and Nutrition Examination survey data. Osteoporos Int 25:1313–1319PubMedCrossRefGoogle Scholar
  99. 99.
    Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, Spanish Society of Rheumatology et al (2011) 2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin 7:357–379, Spanish Google Scholar
  100. 100.
    Etxebarria-Foronda I, Caeiro-Rey JR, Larrainzar-Garijo R et al (2015) Guía SECOT-GEIOS en osteoporosis y fractura por fragilidad. Actualización. Rev Esp Cir Ortop Traumatol 59:373–393PubMedGoogle Scholar
  101. 101.
    García R, Jódar Gimeno E, García Martín A et al (2012) Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Bone Metabolism Working Group of the Spanish Society of Endocrinology. Endocrinol Nutr 59:174–196, Erratum in: Endocrinol Nutr. 2012 59: 469 CrossRefGoogle Scholar
  102. 102.
    Lekamwasam S (2013) Sri Lankan FRAX model and country-specific intervention thresholds. Arch Osteoporos 8:148PubMedCrossRefGoogle Scholar
  103. 103.
    Johansson H, Kanis JA, Ljunggren O, Strom O, Svensson O, Mellstrom D (2011) FRAX—model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines. Lakartidningen 108:336–339PubMedGoogle Scholar
  104. 104.
    Lippuner K, Johansson H, Borgström F et al (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23:2579–2589PubMedCrossRefGoogle Scholar
  105. 105.
    Taiwanese Osteoporosis Association (2012) Taiwanese Guidelines for the Prevention and Treatment of Osteoporosis http://www.iofbonehealth.org/sites/default/files/PDFs/National%20Guidelines/Taiwanese_guidelines_prevention_treatment_osteoporosis.pdf Accessed 22 Oct 2015
  106. 106.
    Pongchaiyakul C, Leerapun T, Wongsiri S, Songpattanasilp T, Taechakraichana N (2012) Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment. J Med Assoc Thai 95:1528–1535PubMedGoogle Scholar
  107. 107.
    Davis S, Martyn-St James M, Sanderson J, et al (2015) Bisphosphonates for preventing osteoporotic fragility fractures (including a partial update of NICE technology appraisal guidance 160 and 161).Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence. Produced by ScHARR, The University of SheffieldGoogle Scholar
  108. 108.
    McCloskey E, Kanis JA, Johansson H et al (2015) FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091–2099PubMedCrossRefGoogle Scholar
  109. 109.
    Lyell V, Henderson E, Devine M, Gregson C (2015) Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing 44:34–41PubMedCrossRefGoogle Scholar
  110. 110.
    Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C (2010) Screening for osteoporosis: systematic review to update the 2002 US Preventive Services Task Force Recommendation. Evidence Syntheses No. 77. AHRQ Publication No. 10-05145-EF-1.Google Scholar
  112. 112.
    Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Care Res 62:1515–1526CrossRefGoogle Scholar
  113. 113.
    Watts NB, Adler RA, Bilezikian JP et al (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822PubMedCrossRefGoogle Scholar
  114. 114.
    Scillitani A, Mazziotti G, Di Somma C et al (2014) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25:441–446PubMedCrossRefGoogle Scholar
  115. 115.
    American College of Obstetricians and Gynecologists (ACOG). Osteoporosis. Washington (DC): American College of Obstetricians and Gynecologists (AC OG); 2012 Sep. 17. p. (ACOG practice bulletin; no. 129)Google Scholar
  116. 116.
    North American Menopause Society (NAMS) (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25–54CrossRefGoogle Scholar
  117. 117.
    Sweet MG, Sweet JM, Jeremiah MP, Galaska SS (2008) Diagnosis and treatment of osteoporosis. Am Fam Physician 79:193–200Google Scholar
  118. 118.
    Adler RA, Hastings FW, Petkov VI (2010) Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 21:647–653PubMedCrossRefGoogle Scholar
  119. 119.
    Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32Google Scholar
  120. 120.
    Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE (2015) Diagnosis and management of osteoporosis. Am Fam Physician 92:261–268PubMedGoogle Scholar
  121. 121.
    Institute for Clinical Systems Improvement (2013) Diagnosis and treatment of osteoporosis. http://www.isci.org/guidelines_more Accessed 29 Jan 2016
  122. 122.
    Florence R, Allen S, Benedict L et al (2013) Diagnosis and treatment of osteoporosis. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_musculoskeletal_guidelines/osteoporosis/ Accessed 1 November 2015
  123. 123.
    Tosteson AN, Melton LJ 3rd, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Berry SD, Kiel DP, Donaldson MG et al (2010) Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int 21:53–60PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21:41–52PubMedCrossRefGoogle Scholar
  126. 126.
    Crandall CJ, Larson J, Gourlay M et al (2014) Osteoporosis screening in postmenopausal women 50–64 years-old: Comparison of U.S. Preventive Services Task Force strategy and two traditional strategies in the Women’s Health Initiative. J Bone Miner Res 29:1661–1666PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Kanis JA, Harvey N, McCloskey EV (2014) Pre-screening young postmenopausal women for BMD testing. BoneKEy Reports 3, Article number: 544 doi: 10.1038/bonekey.39, Published online 11 June 2014
  128. 128.
    Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C (1998) Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 4:37–48PubMedGoogle Scholar
  129. 129.
    Koh LK, Sedrine WB, Torralba TP et al (2001) A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 12:699–705PubMedCrossRefGoogle Scholar
  130. 130.
    Bansal S, Pecina JL, Merry SP et al (2015) US Preventative Services Task Force FRAX threshold has a low sensitivity to detect osteoporosis in women ages 50–64 years. Osteoporos Int 26:1429–1433PubMedCrossRefGoogle Scholar
  131. 131.
    National Osteoporosis Foundation (NOF) (2008) Clinician’s Guide to prevention and treatment of osteoporosis. DC National Osteoporosis Foundation, WashingtonGoogle Scholar
  132. 132.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol (Oxford) 39:1383–1389CrossRefGoogle Scholar
  133. 133.
    Orimo H, Hayashi Y, Fukunaga M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. Jap J Bone Miner Metab 19:331–337CrossRefGoogle Scholar
  134. 134.
    Fujiwara S, Nakamura T, Orimo H (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19:429–435PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390–406PubMedCrossRefGoogle Scholar
  136. 136.
    Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. RCP, LondonGoogle Scholar
  137. 137.
    Hwang J, Chan D, Chen J, Cheng T, Wu C, Soong Y et al (2013) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab 31:1–7CrossRefGoogle Scholar
  138. 138.
    Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396PubMedCrossRefGoogle Scholar
  139. 139.
    Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F (2009) Oden A and the National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos Int 1395:499–1408, Erratum in Osteoporos Int 2009;20:499–502 CrossRefGoogle Scholar
  140. 140.
    Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRefGoogle Scholar
  141. 141.
    Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913PubMedCrossRefGoogle Scholar
  142. 142.
    Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256CrossRefGoogle Scholar
  143. 143.
    Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907–915PubMedCrossRefGoogle Scholar
  144. 144.
    Kyriakos G, Vidal-Casariego A, Fernandez-Martinez MN et al (2015) Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom 18:533–538PubMedCrossRefGoogle Scholar
  145. 145.
    Chen JS, Simpson JM, Blyth FM, March LM (2014) Managing osteoporosis with FRAX (R) in Australia: proposed new treatment thresholds from the 45 &Up Study cohort. Bone 69:148–153PubMedCrossRefGoogle Scholar
  146. 146.
    Johansson H, Kanis JA, McCloskey EV et al (2011) A FRAX (R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRefGoogle Scholar
  147. 147.
    Zerbini CAF, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos 10:224PubMedCrossRefGoogle Scholar
  148. 148.
    Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRefGoogle Scholar
  149. 149.
    Niskanen L, Kettunen J, Koski A-M et al for the Finnish Medical Society Duodecim, Finnish Endocrine Society and Finnish Gynaecological Association (National) (2014) Osteoporosis. Current care guidelines. Suomalaisen Lääkäriseuran Duodecimin, Suomen Endokrinologiyhdistyksen ja Suomen Gynekologiyhdistyksen asettama työryhmä (2014) Osteoporoosi. http://www.terveysportti.fi/xmedia/hoi/hoi24065.pdf Accessed 26 Oct 2015
  150. 150.
    Briot K, Cortet B, Thomas T et al (2012) 2010 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304–313PubMedCrossRefGoogle Scholar
  151. 151.
    McGowan B, Kanis JA, Johansson H, Silke C, Whelan B (2013) Development and use of FRAX in the management of osteoporosis in Ireland. Arch Osteoporos 8:146. doi: 10.1007/s11657-013-0146-z PubMedCrossRefGoogle Scholar
  152. 152.
    Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos 8:164PubMedCrossRefGoogle Scholar
  153. 153.
    Lesnyak O, Ershova O, Belova K et al (2012) Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos 7:67–73. doi: 10.1007/s11657-012-0082-3 PubMedCrossRefGoogle Scholar
  154. 154.
    Russian Association on Osteoporosis (2013) http://www.osteoporoz.ru/content/view/891/113/ Accessed 22 Oct 2015
  155. 155.
    International Osteoporosis Foundation (2012) Ministry of Health official officially launches FRAX model in Sri Lanka http://www.iofbonehealth.org/ministry-health-official-officially-launches-frax-model-sri-lanka Accessed 21 Oct 2015
  156. 156.
    Association Suisse Contre l’Ostéoporose (2015) www.svgo.ch Accessed 18 Oct 2015
  157. 157.
    Nottinghamshire Osteoporosis Guidelines 2014 http://www.nottsapc.nhs.uk/attachments/article/3/osteoporosis%20guideline.pdf Accessed 1 Nov 2015
  158. 158.
    Bruyere O, Fossi M, Zegels D, Leonori L, Hiligsmann M, Neuprez A, Reginster JY (2013) Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 33:973–978PubMedCrossRefGoogle Scholar
  159. 159.
    National Clinical Guideline Centre (2012) Osteoporosis: fragility fracture risk. Osteoporosis: assessing the risk of fragility fracture. Short clinical guideline—CG146 Evidence and recommendations August 2012. Published by the National Clinical Guideline Centre by the Royal College of Physicians, LondonGoogle Scholar
  160. 160.
    Shepstone L, Lenaghan E, Cooper et al (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the ‘SCOOP’ Study. Osteoporos Int 23:2507–2515PubMedCrossRefGoogle Scholar
  161. 161.
    Strom O, Borgstrom F, Kleman M et al (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430–437PubMedCrossRefGoogle Scholar
  162. 162.
    Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24:1491–1502PubMedCrossRefGoogle Scholar
  163. 163.
    Michigan Quality Improvement Consortium Guideline (2014) Management and prevention of osteoporosis Michigan quality improvement consortium Accessed 25 Oct 2015Google Scholar
  164. 164.
    Kanis JA, Adams J, Borgstrom F et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRefGoogle Scholar
  165. 165.
    Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505PubMedCrossRefGoogle Scholar
  166. 166.
    Jonsson B, Strom O, Eisman JA et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982PubMedCrossRefGoogle Scholar
  167. 167.
    Ivergard M, Strom O, Borgstrom F, Burge RT, Tosteson AN, Kanis J (2010) Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone 47:966–974PubMedCrossRefGoogle Scholar
  168. 168.
    Borgstrom F, Strom O, Coelho J et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339–349PubMedCrossRefGoogle Scholar
  169. 169.
    Borgstrom F, Strom O, Kleman M et al (2010) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955–965PubMedCrossRefGoogle Scholar
  170. 170.
    Azagra R, Roca G, Martin-Sanchez et al (2015) FRAX thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population. Med Clin (Barc) 144:1–8CrossRefGoogle Scholar
  171. 171.
    National Institute for Health and Clinical Excellence (2010) Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Technology appraisal 204 http://guidance.nice.org.uk/TA204 Accessed 24 May 2011
  172. 172.
    National Institute for Health and Clinical Excellence (2011a) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal TA160. http://guidance.nice.org.uk/TA160 Accessed 24 May 2011
  173. 173.
    National Institute for Health and Clinical Excellence (2011b) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal TA161. http://egap.evidence.nhs.uk/TA161 Accessed 24 May 2011
  174. 174.
    Kanis JA, McCloskey E, Jönsson B, Cooper A, Ström O, Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos 5:19–48CrossRefGoogle Scholar
  175. 175.
    Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18:9–23PubMedCrossRefGoogle Scholar
  176. 176.
    Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures scores. Br Med J 339:b4229CrossRefGoogle Scholar
  177. 177.
    Chen P, Krege JH, Adachi JD et al (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner 24:495–502CrossRefGoogle Scholar
  178. 178.
    Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX® tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort. J Bone Miner Res 25:2101–2107PubMedCrossRefGoogle Scholar
  179. 179.
    Bolland MJ, Siu AT, Mason BH et al (2011) Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 26:420–427PubMedCrossRefGoogle Scholar
  180. 180.
    Ensrud KE, Lui LY, Taylor BC et al (2009) A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 169:2087–2094PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 25:1002–1009PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Donaldson MG, Palermo L, Schousboe JT, Ensrud KE, Hochberg MC, Cummings SR (2009) FRAX and risk of vertebral fractures: the fracture intervention trial. J Bone Miner Res 24:1793–1799PubMedCrossRefGoogle Scholar
  183. 183.
    Hillier TA, Cauley JA, Rizzo JH (2011) The WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res 26:1774–1782PubMedPubMedCentralCrossRefGoogle Scholar
  184. 184.
    Pluskiewicz W, Adamczyk P, Franek E et al (2010) Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al.—conformity between methods and their clinical utility. Bone 46:1661–1667PubMedCrossRefGoogle Scholar
  185. 185.
    Tamaki J, Iki M, Kadowaki E, Sato Y et al (2011) The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25:71–76Google Scholar
  186. 186.
    Azagra R, Roca G, Encabo G et al (2012) FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord 13:204. doi: 10.1186/1471-2474-13-204 PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV (2010) Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and Garvan nomogram. Osteoporos Int 21:863–871PubMedCrossRefGoogle Scholar
  188. 188.
    Leslie WD, Lix LM (2014) Comparison between various fracture risk assessment tools. Osteoporos Int 25:1–21PubMedCrossRefGoogle Scholar
  189. 189.
    Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431PubMedCrossRefGoogle Scholar
  190. 190.
    Marques A, Ferreira RJO, Santos E, Loza E, Carmona L, Pereira da Silva JA (2015) The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. Downloaded from http://ard.bmj.com/ on 7 Aug 2015
  191. 191.
    Nayak S, Edwards DL, Saleh AA, Greenspan SL (2015) Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 26:1543–1554PubMedPubMedCentralCrossRefGoogle Scholar
  192. 192.
    Kanis JA, Odén A, Johansson H, McCloskey EV (2013) Pitfalls in the external validation of FRAX: response to Bolland et al. Osteoporos Int 24:391–392PubMedCrossRefGoogle Scholar
  193. 193.
    Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRefGoogle Scholar
  194. 194.
    Leslie WD, Lix LM, Johansson H et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRefGoogle Scholar
  195. 195.
    Rubin KH, Abrahamsen B, Hermann AP et al (2011) Fracture risk assessed by fracture risk assessment tool (FRAX) compared with fracture risk derived from population fracture rates. Scand J Public Health 39:312–318PubMedCrossRefGoogle Scholar
  196. 196.
    Sund R, Honkanen R, Johansson H, Oden A, McCloskey EV, Kanis JA, Kröger H (2014) Evaluation of the FRAX model for the prediction of hip fractures in Kuopio, Finland. Calcif Tiss Int 95:39–45CrossRefGoogle Scholar
  197. 197.
    Sund R (2007) Utilization of routinely collected administrative data in monitoring of aging-dependent hip fracture incidence. Epidemiol Perspect Innov 4:2PubMedPubMedCentralCrossRefGoogle Scholar
  198. 198.
    Sund R (2006) Hip fracture incidence in Finland, 1998–2002. Duodecim 122(9):1085–1091PubMedGoogle Scholar
  199. 199.
    Abrahamsen B, Vestergaard P, Rud B et al (2006) Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish osteoporosis prevention study. J Bone Miner Res 21:796–800PubMedCrossRefGoogle Scholar
  200. 200.
    Azagra R, Roca G, Zwart M, Encabo G (2011) Differences in the predictive values of the FRAX (TM) tool between the Spanish and United Kingdom population and considerations about the intervention threshold. Med Clin (Barc) 137(15):713–714CrossRefGoogle Scholar
  201. 201.
    Ettinger B, Ensrud KE, Blackwell T et al (2013) Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 24:1185–1193PubMedCrossRefGoogle Scholar
  202. 202.
    Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192PubMedPubMedCentralCrossRefGoogle Scholar
  203. 203.
    Pressman AR, Lo JC, Chandra M, Ettinger B (2011) Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated healthcare delivery system. J Clin Densitom 14:407–415PubMedCrossRefGoogle Scholar
  204. 204.
    Donaldson MG, Cawthon PM, Schousboe JT et al (2011) Novel methods to evaluate fracture risk models. J Bone Miner Res 26:1767–1773PubMedPubMedCentralCrossRefGoogle Scholar
  205. 205.
    Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fractures. Osteoporos Int 7:407–413PubMedCrossRefGoogle Scholar
  206. 206.
    Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, the IOF CSA Working Group on Fracture Epidemiology (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedPubMedCentralCrossRefGoogle Scholar
  207. 207.
    Kanis JA, Johansson H, Odén A, Dawson-Hughes B, Melton LJ 3rd, McCloskey EV (2010) The effects of a FRAX® revision for the USA. Osteoporos Int 21:35–40PubMedCrossRefGoogle Scholar
  208. 208.
    Brennan SL, Quirk SE, Hosking SM et al (2015) Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with and without bone density measures? Data from the Geelong Osteoporosis Study of Female Cohort. Calcif Tissue Int 96:138–144PubMedCrossRefGoogle Scholar
  209. 209.
    Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis J (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251PubMedCrossRefGoogle Scholar
  210. 210.
    Johansson H, Odén A, Lorentzon M et al (2015) Is the Swedish FRAX model appropriate for immigrants to Sweden? Osteoporos Int 26:2617–2622PubMedCrossRefGoogle Scholar
  211. 211.
    Leslie WD, Berger C, Langsetmo L et al (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22:1873–1883PubMedCrossRefGoogle Scholar
  212. 212.
    Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675–1682PubMedCrossRefGoogle Scholar
  213. 213.
    Yoon J, Kwon S-R, Lim M-J et al (2010) A comparison of three different guidelines for osteoporosis treatment in patients with rheumatoid arthritis in Korea. Korean J Intern Med 25:436–446PubMedPubMedCentralCrossRefGoogle Scholar
  214. 214.
    Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747–1753PubMedCrossRefGoogle Scholar
  215. 215.
    Leslie W, Morin S, Majumdar S et al (2016) Net reclassification Improvement with FRAX versus a simpler risk assessment system: more is more. J Bone Miner Res 30:S103 (Paper accepted Osteoporos Int, Feb 2016) Google Scholar
  216. 216.
    Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. J Bone Miner Metab 30:700–705PubMedCrossRefGoogle Scholar
  217. 217.
    Borgstrom F, Johnell O, Kanis JA et al (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459–1471PubMedCrossRefGoogle Scholar
  218. 218.
    Oden A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92:42–49PubMedCrossRefGoogle Scholar
  219. 219.
    McCloskey EV, Johansson H, Harvey NC, Compston J, Kanis JA (2015) Online linkage of FRAX fracture risk assessment to management guidance is used by clinical practitioners. An analysis of access to National Osteoporosis Guideline Group Guidance in the UK (July 2013-June2014). J Bone Miner Res 30:S290–S291, (Paper accepted Osteoporos Int, June 2016) Google Scholar
  220. 220.
    Crabtree NJ, Bebbington NA, Chapman DM et al (2010) Impact of UK National Guidelines based on FRAX(R)—comparison with current clinical practice. Clin Endocrinol 73:452–456Google Scholar
  221. 221.
    Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, and the Epidemiology and Quality of Life Working Group of IOF (2013) Worldwide uptake of FRAX. Arch Osteoporos 8:166. doi: 10.1007/s11657-013-0166-8 CrossRefGoogle Scholar
  222. 222.
    Brennan SL, Leslie WD, Leslie WD, Lix LM et al (2014) FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int 25:61–69PubMedCrossRefGoogle Scholar
  223. 223.
    Kayan K, Johansson H, Oden A et al (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporos Int 20:2055–2061PubMedCrossRefGoogle Scholar
  224. 224.
    McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  225. 225.
    Harvey NC, Johansson H, Odén A et al (2016) FRAX predicts incident falls in elderly men. Findings from MrOs Sweden. Osteoporos Int 27:267–274PubMedCrossRefGoogle Scholar
  226. 226.
    Johansson J, Harvey N, Odén A et al (2015) The predictive value of falls history for incident fracture decreases with time: MrOs Sweden. J Bone Miner Res 30:S424Google Scholar
  227. 227.
    Cauley JA, El-Hajj Fuleihan G, Luckey MM, FRAX® Position Development Conference Members (2011) Official positions for FRAX clinical regarding international differences. FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom 14:237–239PubMedCrossRefGoogle Scholar
  228. 228.
    van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8(3):131–137PubMedPubMedCentralCrossRefGoogle Scholar
  229. 229.
    Leslie WD, Majumdar SR, Lix LM et al (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391–397PubMedCrossRefGoogle Scholar
  230. 230.
    Leslie WD, Morin S, Lix LM et al (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2016

Authors and Affiliations

  • John A. Kanis
    • 1
    • 2
    Email author
  • Nicholas C. Harvey
    • 3
  • Cyrus Cooper
    • 3
  • Helena Johansson
    • 1
  • Anders Odén
    • 1
  • Eugene V. McCloskey
    • 1
  • The Advisory Board of the National Osteoporosis Guideline Group
  1. 1.Centre for Metabolic DiseasesUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Institute of Health and AgeingAustralian Catholic UniversityMelbourneAustralia
  3. 3.MRC Lifecourse Epidemiology UnitUniversity of SouthamptonSouthamptonUK

Personalised recommendations